Skip to main content
Sign In

Peter Anderson, PharmD

Director of the Pharmaceutical Sciences Graduate Program

Professor, Department of Pharmaceutical Sciences

Mailing address:

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Mail Stop C238
12850 E. Montview Blvd. V20-4101
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4101

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4410A/D


Training and Education:

  • 1998-2001 Fellowship: Clinical Pharmacology of Antiviral Compounds; University of Minnesota, Minneapolis
  • 1994-1998 Doctor of Pharmacy, University of Minnesota, Minneapolis, College of Pharmacy
  • 1985-1991 Bachelor of Science in Biology, University of Minnesota, St Paul

Clinical / Research Interest:

The clinical pharmacology of antiretroviral medications with a focus on the cellular pharmacology of nucleoside analogs for prevention of HIV infection and pharmacological approaches to monitor medication adherence.


  • Professional 2nd year Fall: Pharmacokinetics (Course Director)
  • Professional 3rd year Fall: Pharmacotherapy VI Infectious Diseases 2 (Lecturer)
  • Graduate Fall: Fundamentals of Pharmaceutical Sciences (Course Director)
  • Graduate Fall: Pharmacokinetic Principles and Applications (Co-Course Director)

Representative Publications:

  • Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM; For the iPrEx Study Team. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Sci Transl Med. 2012 Sep 12;4(151):151ra125. []
  • Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2 2010 Dec 30;363(27):2587-99. Epub 2010 Nov 23.
  • Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacologic considerations for tenofovir and emtricitabine to prevent HIV infection.J Antimicrob Chemother. 2010. Nov 30. [Epub ahead of print]
  • Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
  • Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLOS ONE. 2014 Jan 8;9(1):e83736
  • Wempe MF and Anderson PL. Atazanavir metabolism according to CYP3A5 status: An in vitro - in vivo assessment. Drug Metabolism and Disposition. 2011 Mar;39(3):522-7. Epub 2010 Dec 9.
  • Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, and MaWhinney S. Atazanavir pharmacokinetics in genetically-determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov;64(5):1071-9
  • Center for Translational Pharmacokinetics and Pharmacogenomics
  • Recent Publications

​​​In the News